Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study

被引：0
|
作者：
Arnaud Bayle
Laila Belcaid
Lola-Jade Palmieri
Diego Teysonneau
Sophie Cousin
Mariella Spalato-Ceruso
Mihaela Aldea
Damien Vasseur
Melissa Alame
Laura Blouin
Isabelle Soubeyran
Claudio Nicotra
Maud Ngocamus
Antoine Hollebecque
Yohann Loriot
Benjamin Besse
Ludovic Lacroix
Etienne Rouleau
Fabrice Barlesi
Fabrice Andre
Antoine Italiano
机构：
[1] DITEP,Department of Oncology
[2] Gustave Roussy,Department of Medicine
[3] Copenhagen University Hospital,Department of Medicine
[4] Institut Bergonié,Department of Biopathology
[5] Gustave Roussy,Department of Biopathology
[6] Gustave Roussy,Faculty of Medicine
[7] Institut Bergonié,Faculty of Medicine
[8] Paris Saclay University,undefined
[9] University of Bordeaux,undefined
来源：
Molecular Cancer | / 22卷
关键词：
ctDNA; Targeted therapy; Resistance biomarkers; Next-generation sequencing;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 40 条
  • [31] Prognostic value of circulating tumor DNA (ctDNA) detection during adjuvant chemotherapy in patients with stage III colorectal cancer: The interim report of a prospective, observational study
    Peng, Junjie
    Li, Yaqi
    Mo, Shaobo
    Ma, Xiaoji
    Hu, Xiang
    Zhang, Long
    Huang, Dan
    Cai, Sanjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] The association of disease free survival and the impact of tumor subtype on overall survival in advanced breast cancer patients: A real-world study from the China National Cancer Center
    Li, Yiqun
    Xu, Binghe
    Ma, Fei
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Wang, Jiayu
    Luo, Yang
    Cai, Ruigang
    Li, Qiao
    Mo, Hongnan
    Guan, Xiuwen
    Lin, Shaoyan
    Chen, Yimeng
    Wang, Zijing
    CANCER RESEARCH, 2020, 80 (04)
  • [33] Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial
    Montagut, Clara
    Argiles, Guillem
    Ciardiello, Fortunato
    Poulsen, Thomas T.
    Dienstmann, Rodrigo
    Kragh, Michael
    Kopetz, Scott
    Lindsted, Trine
    Ding, Cliff
    Vidal, Joana
    Clausell-Tormos, Jenifer
    Siravegna, Giulia
    Sanchez-Martin, Francisco J.
    Koefoed, Klaus
    Pedersen, Mikkel W.
    Grandal, Michael M.
    Dvorkin, Mikhail
    Wyrwicz, Lucjan
    Rovira, Ana
    Cubillo, Antonio
    Salazar, Ramon
    Desseigne, Francoise
    Nadal, Cristina
    Albanell, Joan
    Zagonel, Vittorina
    Siena, Salvatore
    Fumi, Guglielmo
    Rospo, Giuseppe
    Nadler, Paul
    Horak, Ivan D.
    Bardelli, Alberto
    Tabernero, Josep
    JAMA ONCOLOGY, 2018, 4 (04)
  • [34] Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study
    Martelli, V.
    Vidal Barrull, J.
    Fernandez Rodriguez, C.
    Garcia Alfonso, P.
    Paez, D.
    Gibert, J.
    Alonso, V.
    Gomez Espana, M. A.
    Santos Vivas, C.
    Duran Ogalla, G.
    Elez Fernandez, M. E.
    Garcia-Carbonero, R.
    Ferreiro Monteagudo, R.
    Manzano Mozo, J. L.
    Losa, F.
    Bellosillo Paricio, B.
    Tabernero, J.
    Salazar Soler, R.
    Aranda Aguilar, E.
    Montagut Viladot, C.
    ANNALS OF ONCOLOGY, 2024, 35 : S51 - S52
  • [35] Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study
    Lipsyc-Sharf, Marla
    Fitzsimmons, Kasey
    Medford, Arielle J.
    Podany, Emily L.
    Sedrak, Mina S.
    McAndrew, Nicholas Patrick
    Callahan, Rena Desai
    Kapoor, Nimmi S.
    Master, Aashini K.
    Rivero-Hinojosa, Samuel
    Fielder, Janie
    Rodriguez, Angel A.
    Liu, Minetta C.
    Knape, Justine
    Donahue, Jeannine
    Gianni, Caterina
    Davis, Andrew A.
    Cristofanilli, Massimo
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients - PLCRC-PROVENC3 study
    Alarcon, Carmen Rubio
    van der Kruijssen, Dave E.
    Schraa, Suzanna J.
    Nassau, Sietske C.
    Leon, Leticia G.
    Meiqari, Lana
    Bosch, Linda J.
    Simmons, John K.
    Sausen, Mark
    Greer, Amy
    Angiuoli, Samuel V.
    Roodhart, Jeanine M.
    Velculescu, Victor E.
    van den Broek, Daan
    Punt, Cornelis J.
    Coupe, Veerle M.
    Koopman, Miriam
    Meijer, Gerrit A.
    Vink, Geraldine R.
    Fijneman, Remond J.
    CANCER RESEARCH, 2022, 82 (12)
  • [37] Updated results of a prospective observational multicenter study on resistance mechanisms to osimertinib using circulating tumor DNA analyses in EGFR-mutated non- small cell lung cancer patients (ELUCIDATOR study)
    Osuga, Mitsuo
    Tamiya, Akihiro
    Harada, Daijiro
    Mizumori, Yasuyuki
    Isa, Shun-ichi
    Taniguchi, Yoshihiko
    Nakamura, Keiichi
    Shinohara, Tsutomu
    Yanai, Hidetoshi
    Nakatomi, Katsumi
    Oki, Masahide
    Mori, Masahide
    Kuwako, Tomohito
    Yamazaki, Koji
    Tamura, Atsuhisa
    Ando, Masahiko
    Koh, Yasuhiro
    CANCER RESEARCH, 2024, 84 (06)
  • [38] Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFRTherapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial (vol 4, e175245, 2018)
    Montagut, Clara
    Argiles, Guillem
    Ciardiello, Fortunato
    Poulsen, Thomas T.
    Dienstmann, Rodrigo
    Kragh, Michael
    Kopetz, Scott
    Lindsted, Trine
    Ding, Cliff
    Vidal, Joana
    Clausell-Tormos, Jenifer
    Siravegna, Giulia
    Sanchez-Martín, Francisco J.
    Koefoed, Klaus
    Pedersen, Mikkel W.
    Grandal, Michael M.
    Dvorkin, Mikhail
    Wyrwicz, Lucjan
    Rovira, Ana
    Cubillo, Antonio
    Salazar, Ramon
    Desseigne, Francoise
    Nadal, Cristina
    Albanell, Joan
    Zagonel, Vittorina
    Siena, Salvatore
    Fumi, Guglielmo
    Rospo, Giuseppe
    Nadler, Paul
    Horak, Ivan D.
    Bardelli, Alberto
    Tabernero, Josep
    JAMA ONCOLOGY, 2019, 5 (05) : 745 - 745
  • [39] Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)
    Nakamura, Y.
    Kotani, D.
    Saori, M.
    Yukami, H.
    Watanabe, J.
    Akazawa, N.
    Kataoka, K.
    Hirata, K.
    Yamazaki, K.
    Yeh, K-H.
    Laliotis, G.
    Aushev, V.
    Jurdi, A.
    Kotaka, M.
    Bando, H.
    Taniguchi, H.
    Takemasa, I.
    Kato, T.
    Yoshino, T.
    Oki, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S415 - S416
  • [40] Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib plus fulvestrant plus trastuzumab (N plus F plus T)
    Ma, Cynthia
    Waisman, James
    Brufsky, Adam M.
    Yang, Eddy S.
    Wildiers, Hans
    Crown, John P.
    Piha-Paul, Sarina A.
    Suga, Jennifer M.
    Garcia-Saenz, Jose Angel
    Gambardella, Valentina
    Guerrero, Angel
    Stemmer, Salomon
    Bose, Ron
    Novara-Demgen, Tonya
    DiPrimeo, Daniel
    Eli, Lisa D.
    Jhaveri, Komal
    CANCER RESEARCH, 2023, 83 (05)
1234